Risk of fetal hydrops and non-hydropic late intrauterine fetal death after gestational parvovirus B19 infection.
BACKGROUND
Risk assessment of parvovirus B19 (B19)-associated fetal complications following gestational B19 infection remains controversial.


OBJECTIVE
To determine the risk of fetal hydrops or non-hydropic late intrauterine fetal death following acute maternal B19 infection at defined gestational weeks.


METHODS
Observational cohort study of pregnant women with serologic evidence of acute B19 infection. If available, fetal or neonatal tissue samples from cases complicated by fetal loss or hydrops were investigated for the presence of B19 DNA by polymerase chain reaction (PCR) and/or in situ hybridization (ISH).


RESULTS
Of 236 women with known pregnancy outcome, 228 had a live birth and 8 a fetal loss. The observed rate of fetal hydrops for all pregnant women was 4.2% (10/236) (95% confidence interval [CI], 2.1-7.7) and 10.6% (10/94) (95% CI, 5.2-18.7) for those infected between 9 and 20 weeks gestation. Tissue samples from 8 hydrops cases were investigated by PCR or ISH and all were B19 DNA positive. Fetal death occurring during or after gestational week 22 was only observed in one case which was associated with B19-derived fetal hydrops.


CONCLUSIONS
Our findings demonstrate that although adverse fetal outcome is a rare complication of gestational B19 infection, a relevant risk of fetal hydrops exists particularly for women infected between 9 and 20 weeks' gestation. Cases of B19-derived non-hydropic late intrauterine fetal death were not observed in the present study.
Enders
Martin
M
Laboratory Prof G. Enders and Partners & Institute of Virology, Infectious Diseases and Epidemiology e.V., Rosenbergstrasse 85, D-70193 Stuttgart, Germany. menders@labor-enders.de
Klingel
Karin
K
Weidner
Andrea
A
Baisch
Carola
C
Kandolf
Reinhard
R
Schalasta
Gunnar
G
Enders
Gisela
G
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D015331:Cohort Studies; D004279:DNA, Viral / Q000235:genetics / Q000302:isolation & purification; D005260:Female; D006801:Humans; D015160:Hydrops Fetalis / Q000453:epidemiology* / Q000821:virology*; D007231:Infant, Newborn; D009693:Nucleic Acid Hybridization; D010322:Parvoviridae Infections / Q000453:epidemiology* / Q000401:mortality; D016732:Parvovirus B19, Human / Q000302:isolation & purification*; D016133:Polymerase Chain Reaction; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000453:epidemiology* / Q000821:virology; D018570:Risk Assessment
D000914:Antibodies, Viral; D004279:DNA, Viral